Iovance Biotherapeutics, Inc. income statement

In fiscal 2025, Iovance Biotherapeutics, Inc. reported revenue of $264m, up 60.6% on the year before, operating income of −$403m (a -153.1% margin) and net income of −$391m, or −$1.09 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Iovance Biotherapeutics, Inc.: income statement, annual
Fiscal year	2013Dec 2013	2014Dec 2014	2015Dec 2015	2016Dec 2016	2017Dec 2017	2018Dec 2018	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMJun 2026
Revenue	0	0	0	0	0	0	1	164	264	325
Cost of revenue	—	—	—	—	—	—	1	93	173	168
Gross profit	—	—	—	—	—	—	0	71	90	157
Research and development	2	4	15	27	72	100	333	276	300	268
General and administrative	4	8	12	27	21	28	106	152	152	149
Operating income	−23	−12	−28	−54	−93	−128	−461	−395	−403	−301
Interest expense	0	−0	—	—	—	—	—	—	—	—
Net interest income	−0	0	0	—	—	—	—	—	—	—
Income before tax	—	—	—	—	—	—	−448	−375	−393	−294
Income tax	—	0	0	0	0	0	−3	−3	−2	−4
Net income	−25	−12	−28	−53	−92	−124	−444	−372	−391	−290
Diluted EPS	−$3.47	−$0.48	−$0.62	−$1.85	−$1.41	−$1.27	−$1.89	−$1.28	−$1.09	−$0.71
Diluted shares (average)	10m	25m	44m	55m	65m	97m	235m	290m	357m	410m
EBITDA	−23	−12	−27	−53	−92	−127	−449	−384	−390	−276

US$ millions unless shown otherwise. Fiscal quarters.

Iovance Biotherapeutics, Inc.: income statement, quarterly
Quarter	2024 Q3Sept 2024	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026
Revenue	59	74	49	60	67	87	71	99
Cost of revenue	32	38	43	49	38	43	42	44
Gross profit	27	36	7	11	29	44	29	56
Research and development	67	71	76	78	75	71	62	59
General and administrative	39	42	44	38	35	36	39	39
Operating income	−89	−87	−121	−114	−95	−73	−81	−52
Income before tax	−85	−77	−118	−110	−94	−72	−80	−49
Income tax	−2	2	−2	2	−2	0	−1	−1
Net income	−84	−79	−116	−112	−91	−72	−79	−47
Diluted EPS	−$0.28	−$0.25	−$0.36	−$0.33	—	—	−$0.19	−$0.11
EBITDA	−86	−83	−119	−110	−86	−70	−78	−42

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: ARVN vs IOVA ADPT vs IOVA IOVA vs VCEL

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Iovance Biotherapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Iovance Biotherapeutics, Inc.